切换至 "中华医学电子期刊资源库"

中华结直肠疾病电子杂志 ›› 2021, Vol. 10 ›› Issue (03) : 237 -242. doi: 10.3877/cma.j.issn.2095-3224.2021.03.003

论著

多靶点粪便FIT-DNA检测技术在结直肠癌患者、配偶及一级亲属筛查中的应用研究
关旭1, 马晨曦1, 王炜2, 朱德祥3, 庄奥博3, 王若谷4, 陈创奇5, 李佳英6, 裴海平7, 魏少忠8, 许剑民3, 孙学军2, 王锡山1,()   
  1. 1. 100021 北京,国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院结直肠外科
    2. 710061 西安交通大学第一附属医院普通外科
    3. 200032 上海,复旦大学附属中山医院普外科
    4. 250031 济南,山东第一医科大学第三附属医院(山东省医科院附属医院)胃肠外科
    5. 510080 广州,中山大学附属第一医院胃肠外科中心结直肠外科
    6. 150001 哈尔滨医科大学附属第二医院结直肠肿瘤外科
    7. 410008 长沙,中南大学湘雅医院普外科
    8. 430079 武汉,湖北省肿瘤医院胃肠外科
  • 收稿日期:2020-07-17 出版日期:2021-06-25
  • 通信作者: 王锡山
  • 基金资助:
    北京市科技计划(D171100002617002,D171100002617004)

Application of multitarget stool FIT-DNA test for cancer screening in colorectal cancer patients and their spouses and first-degree relatives

Xu Guan1, Chenxi Ma1, Wei Wang2, Dexiang Zhu3, Aobo Zhuang3, Ruogu Wang4, Chuangqi Chen5, Jiaying Li6, Haiping Pei7, Shaozhong Wei8, Jianmin Xu3, Xuejun Sun2, Xishan Wang1,()   

  1. 1. Department of Colorectal Surgery, National Cancer Center /National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
    2. Department of General Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China
    3. Department of General Surgery, Affiliated Zhongshan Hospital of Fudan University, Shanghai 200032, China
    4. Department of Gastrointestinal Surgery, The Third Affiliated Hospital of Shandong First Medical University (Affiliated Hospital of Shandong Medical College), Ji'nan 250031, China
    5. Department of Colorectal Surgery, Gastrointestinal Surgery Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China
    6. Department of Colorectal Cancer Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin 150001, China
    7. Department of General Surgery, Xiangya Hospital of Central South University, Changsha 410008, China
    8. Department of Gastrointestinal Surgery, Hubei Cancer Hospital, Wuhan 430079, China
  • Received:2020-07-17 Published:2021-06-25
  • Corresponding author: Xishan Wang
引用本文:

关旭, 马晨曦, 王炜, 朱德祥, 庄奥博, 王若谷, 陈创奇, 李佳英, 裴海平, 魏少忠, 许剑民, 孙学军, 王锡山. 多靶点粪便FIT-DNA检测技术在结直肠癌患者、配偶及一级亲属筛查中的应用研究[J/OL]. 中华结直肠疾病电子杂志, 2021, 10(03): 237-242.

Xu Guan, Chenxi Ma, Wei Wang, Dexiang Zhu, Aobo Zhuang, Ruogu Wang, Chuangqi Chen, Jiaying Li, Haiping Pei, Shaozhong Wei, Jianmin Xu, Xuejun Sun, Xishan Wang. Application of multitarget stool FIT-DNA test for cancer screening in colorectal cancer patients and their spouses and first-degree relatives[J/OL]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2021, 10(03): 237-242.

目的

初步探究多靶点粪便FIT-DNA检测技术对结直肠癌筛查的有效性,同时探索结直肠癌患者配偶及其一级亲属的结直肠癌及癌前病变发病风险。

方法

采用新型多靶点粪便FIT-DNA联合检测技术对于2017年4月至2019年3月全国八家医院的结直肠外科或普外科就诊的结直肠癌患者、患者配偶及一级亲属进行检测,并结合肠镜结果评价其检测性能。

结果

共211名受试者均完成多靶点粪便FIT-DNA联合检测及肠镜检查,其中135例为结直肠癌患者(64.0%),47例为患者配偶(22.3%),29例为患者一级亲属(13.7%)。其中,患者配偶的肠镜病变检出率为14.9%(7/47),患者一级亲属的肠镜病变检出率为24.1%(7/29),均未有癌变检出。多靶点粪便FIT-DNA联合检测技术检测结直肠癌的敏感性为89.6%(121/135),特异度为96.8%(60/62)。

结论

本研究初步肯定了多靶点粪便FIT-DNA联合检测技术在结直肠癌筛查中的检测性能,为进一步开展大样本前瞻性研究奠定了良好的基础。

Objective

To assess the clinical performance of Multitarget stool FIT-DNA test for colorectal cancer (CRC) screening, and investigate the risk factors of developing colorectal cancer and precancerous lesions in spouses and first-degree relatives of CRC patients.

Methods

CRC patients and their spouses and first-degree relatives were recruited from colorectal surgery or general surgery departments of eight hospitals in China between April 2017 to March 2019. Multitarget stool FIT-DNA test results were compared with colonoscopy outcomes.

Results

Of 211 valid participants, 135 (64.0%) were colorectal cancer patients, 47 (22.3% )were spouses and 29 (13.7%) were first-degree relatives. Colonoscopy revealed 14.9% (7/47) of spouses and 24.1% (7/29) of first-degree relatives had colonoscopic lesions. The sensitivity and specificity of Multitarget stool FIT-DNA test were 89.6% (121/135) and 96.8% (60/62) respectively.

Conclusion

The study confirmed the clinical performance of Multitarget stool FIT-DNA test in CRC screening, and provided essential data for large scale prospective study in the next stage.

表1 211例受试者总体检测情况分析
表2 135例结直肠癌患者检测情况分析
表3 76例患者家属的基本特征及检测情况分析
表4 多靶点粪便FIT-DNA联合检测技术的检测性能
1
Chen W, Zheng R, Baade P, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132.
2
中国抗癌协会大肠癌专业委员会中国结直肠肿瘤早诊筛查策略制订专家组. 中国结直肠肿瘤早诊筛查策略专家共识[J]. 中华胃肠外科杂志, 2018, 21(10): 1081-1086.
3
Butterworth A, Higgins J, Pharoah P. Relative and absolute risk of colorectal cancer for individuals with a family history: A meta-analysis[J]. Eur J Cancer, 2006, 42(2): 216-227.
4
Lew J, St John D, Xu X, et al. Long-term evaluation of benefits, harms, and cost-effectiveness of the National Bowel Cancer Screening Program in Australia: a modelling study[J]. Lancet Public Health, 2017, 2(7): e331-e340.
5
Tanday S. Updated Canadian colorectal cancer screening guidelines[J]. Lancet Oncol, 2016, 17(4): e137.
6
Smith R, Andrews K, Brooks D, et al. Cancer screening in the United States, 2017:A review of current American Cancer Society guidelines and current issues in cancer screening[J]. CA Cancer J Clin, 2017, 67(2): 100-121.
7
Imperiale T, Ransohoff D, Itzkowitz S, et al. Multitarget stool DNA testing for colorectal-cancer screening[J]. N Engl J Med, 2014, 370(14): 1287-1297.
8
Ridge J, Statz S. Exact Sciences' experience with the FDA and CMS parallel review program[J]. Expert Rev Mol Diagn, 2015, 15(9): 1117-1124.
9
马志刚, 朱晓麟, 马丽红, 等. 基于多靶点粪便FIT-DNA 联合检测技术的结直肠癌早期筛查结果分析[J/CD]. 中华结直肠疾病电子杂志, 2019, 8(6): 616-621.
10
Jiayi M, Yangqin H, Shanrong C, et al. Plausibility of an extensive use of stool DNA test for screening advanced colorectal neoplasia[J]. Clin Chim Acta, 2020, 501: 42-47.
11
钟英强, 邹勇男, 李海刚, 等. 大肠癌患者一级亲属的电子肠镜与粪便潜血试验的筛查结果分析[J]. 中华消化内镜杂志, 2006, 23(5): 340-343.
12
Johns L, Houlston R. A systematic review and meta-analysis of familial colorectal cancer risk[J]. Am J Gastroenterol, 2001, 96(10): 2992-3003.
13
Tabung F, Liu L, Wang Wet al. Association of Dietary Inflammatory Potential With Colorectal Cancer Risk in Men and Women[J]. JAMA Oncol, 2018, 5(4):579.
[1] 顾莉莉, 姜凡. 安徽省超声产前筛查切面图像质量现状调查情况及分析[J/OL]. 中华医学超声杂志(电子版), 2024, 21(07): 671-674.
[2] 明昊, 肖迎聪, 巨艳, 宋宏萍. 乳腺癌风险预测模型的研究现状[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(05): 287-291.
[3] 钱警语, 郑明明. 《2024意大利妇产科学会非侵入性和侵入性产前诊断指南》解读[J/OL]. 中华妇幼临床医学杂志(电子版), 2024, 20(05): 486-492.
[4] 罗青杉, 梅海涛, 郝家领, 蔡锦锋, 周润楷, 温玉刚. 连接蛋白43通过调控细胞周期抑制结直肠癌的增殖机制研究[J/OL]. 中华普通外科学文献(电子版), 2024, 18(05): 344-349.
[5] 徐逸男. 不同术式治疗梗阻性左半结直肠癌的疗效观察[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 72-75.
[6] 谢丽春, 欧庆芬, 张秋萍, 叶升. 简化和标准肝脏MRI方案在结直肠癌肝转移患者随访中的临床应用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(04): 434-437.
[7] 严虹霞, 王晓娟, 张毅勋. 2 型糖尿病对结直肠癌患者肿瘤标记物、临床病理及预后的影响[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 483-487.
[8] 赵磊, 刘文志, 林峰, 于剑, 孙铭骏, 崔佑刚, 张旭, 衣宇鹏, 于宝胜, 冯宁. 深部热疗在改善结直肠癌术后辅助化疗副反应及生活质量中的作用研究[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 488-493.
[9] 黄海洋, 邝永龙, 陈嘉胜. 基层医院结直肠肿瘤经自然腔道取标本手术30 例分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 510-518.
[10] 韩加刚, 王振军. 梗阻性左半结肠癌的治疗策略[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 450-458.
[11] 梁轩豪, 李小荣, 李亮, 林昌伟. 肠梗阻支架置入术联合新辅助化疗治疗结直肠癌急性肠梗阻的疗效及其预后的Meta 分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 472-482.
[12] 张蔚林, 王哲学, 白峻阁, 黄忠诚, 肖志刚. 利用TCGA数据库构建基于miRNA的结直肠癌列线图预后模型[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(05): 381-388.
[13] 张伟伟, 陈启, 翁和语, 黄亮. 随机森林模型预测T1 期结直肠癌淋巴结转移的初步研究[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(05): 389-393.
[14] 任佳琪, 刁德昌, 何自衍, 张雪阳, 唐新, 李文娟, 李洪明, 卢新泉, 易小江. 网膜融合线导向的脾曲游离技术在左半结肠癌根治术中的应用[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(05): 362-367.
[15] 张迪, 王春霞, 张学东, 李发馨, 庞淅文, 陈一锋, 张维胜, 王涛. 梗阻性左半结直肠癌自膨式金属支架置入后行腹腔镜手术与开腹手术的短期临床疗效比较[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(05): 375-380.
阅读次数
全文


摘要